Related Articles
Life Sciences A to Z - Q is for Quantum Computing: Opportunities and challenges for life sciences innovation
Find out more
Stephenson Harwood successfully represent GPI SpA in procurement challenge
Find out more
Stephenson Harwood advises on triple acquisition deal for Vulcan Two Group
International law firm Stephenson Harwood has advised Vulcan Two Group plc on its simultaneous acquisition of three companies and £40m fundraising on AIM.
Vulcan Two is aiming to create the UK’s leading regulated ePharmacy platform through buy-and-build. It has acquired three companies – CloudRx Holdings Limited, Hyperdrug Pharmaceuticals Ltd and Webmed Pharmacy Ltd – for an aggregate consideration of up to £41.7 million.
The transaction constituted a reverse takeover under the AIM Rules. Readmission of the enlarged share capital to trading on AIM took place on Thursday 19 March at 8am.
The Stephenson Harwood team was led by Partners Karima Hudson and Tom Page, supported by Managing Associate Gerald Seeto, and Associates Bryton Chin, Sam Tyler, and Eleanor Wardley.
Commenting, Karima Hudson, Partner at Stephenson Harwood, said:
“The ePharmacy market is experiencing rapid growth, and we are delighted to have supported Vulcan Two as part of their acquisition strategy.”
Tom Page, Partner in the Life Sciences and Healthcare sector group at Stephenson Harwood, added:
“Life Sciences and Healthcare is a core focus for the firm. There has been a significant increase in market growth for ePharmacy services, and we are pleased to have used our expertise to support Vulcan Two on this transaction.”